Have a personal or library account? Click to login
Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled Cover

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Open Access
|Jan 2013

References

  1. 1. C. V. Pardeshi, P. V. Rajput, V. S. Belgamwar and A. R. Tekade, Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for valsartan, J. Microencapsul. 29 (2011) 103-114; DOI: 10.3109/02652048.2011.630106.10.3109/02652048.2011.630106
  2. 2. W. Mehnert and K. Mader, Solid lipid nanoparticles: Production, characterization and applications, Adv. Drug. Del. Rev. 47 (2001) 165-196; DOI: 10.1016/S0169-409X(01)00105-3.10.1016/S0169-409X(01)00105-3
  3. 3. S. Mukherjee, S. Ray and R. S. Thakur, Solid lipid nanoparticles: A modern formulation approach in drug delivery system, Ind. J. Pharm. Sci. 71 (2009) 349-358.
  4. 4. R. H. Müller, K. Mäder and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art, Eur. J. Pharm. Biopharm. 50 (2000) 161-177.10.1016/S0939-6411(00)00087-4
  5. 5. R. H. Müller, M. Radtke and S. A. Wissing, Nanostructured lipid matrices for improved microencapsulation of drugs, Int. J. Pharm. 242 (2002) 121-128; DOI: 10.1016/S0378-5173(02)00180-1.10.1016/S0378-5173(02)00180-1
  6. 6. R. H. Müller, M. Radtke and S. A. Wissing, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv. Drug Del. Rev. 54 (Suppl. 1) (2002) S131-S155; DOI: 10.1016/S0169-409X(02)00118-7.10.1016/S0169-409X(02)00118-7
  7. 7. R. H. Müller, R. D. Petersen, A. Hommoss and J. Pardeike, Nanostructured lipid carriers (NLC) for cosmetic dermal products, Adv. Drug Del. Rev. 59 (2007) 522-530; DOI: 10.1016/j.addr.2007.04.012.10.1016/j.addr.2007.04.01217602783
  8. 8. J. Y. Fang, C. L. Fang, C. H. Liu and Y. H. Su, Lipid nanoparticles as vehicles for psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers, Eur. J. Pharm. Biopharm. 70 (2008) 633-640; DOI: 10.1016/j.ejpb.2008.05.008.10.1016/j.ejpb.2008.05.00818577447
  9. 9. E. B. Souto, S. A. Wissing, C. M. Barbosa and R. H. Müller, Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery, Int. J. Pharm. 278 (2004) 71-77; DOI: 10.1016/j.ijpharm.2004.02.032.10.1016/j.ijpharm.2004.02.03215158950
  10. 10. M. Joshi and V. Patravale, Nanostructured lipid carriers (NLC) based gel of celecoxib, Int. J. Pharm. 346 (2008) 124-132; DOI: 10.1016/j.ijpharm.2007.05.060.10.1016/j.ijpharm.2007.05.06017651933
  11. 11. V. Teeranachaideekul, R. H. Müller and V. B. Junyaprasert, Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) - Effect of formulation parameters on physicochemical stability, Int. J. Pharm. 340 (2007) 198-206; DOI: 10.1016/j.ijpharm.2007.03.022.10.1016/j.ijpharm.2007.03.02217482778
  12. 12. S. Doktorovova, J. Araujo, M. L. Garcia, E. Rakovsky and E. B. Souto, Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC), Colloid Surfacec B. 75 (2010) 538-542; DOI: 10.1016/j.colsurfb.2009.09.033.10.1016/j.colsurfb.2009.09.033
  13. 13. C. Olbrich, A. Gessner, W. Schroder, O. Kayser and R. H. Müller, Lipid-drug conjugate of the hydrophilic drug diminazine-cytotoxicity testing and mouse serum adsorption, J. Control. Release 96 (2004) 425-435; DOI: 10.1016/j.jconrel.2004.02.024.10.1016/j.jconrel.2004.02.024
  14. 14. H. L. Wong, A. M. Rauth, R. Bendayan and X. Y. Wu, In-vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model, Eur. J. Pharm. Biopharm. 65 (2007) 300-308; DOI: 10.1016/j.ejpb.2006.10.022.10.1016/j.ejpb.2006.10.022
  15. 15. H. L. Wong, A. M. Rauth, R. Bendayan and X. Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment for multidrug-resistant breast cancer, J. Control. Release 116 (2006) 275-284; DOI: 10.1016/j.jconrel.2006.09.007.10.1016/j.jconrel.2006.09.007
  16. 16. L. Zhang, J. M. Chan, F. X. Gu, A. Z. Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer and O. C. Farokhzad, Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform, ACS Nano. 2 (2008) 1696-1702; DOI: 10.1021/nn800275r.10.1021/nn800275r
  17. 17. Y. Li, H. L. Wong, A. J. Shuhendler, A. M. Rauth and X. Y. Wu, Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles, J. Control. Release. 128 (2008) 60-70; DOI: 10.1016/j.jconrel.2008.02.014.10.1016/j.jconrel.2008.02.014
  18. 18. C. Salvador-Morales, L. Zhang, R. Langer and O. C. Farokhzad, Immunocompatibility properties of polymer-lipid hybrid nanoparticles with heterogeneous surface functional groups, Biomaterials 30 (2009) 2231-2240; DOI: 10.1016/j.biomaterials.2009.01.005.10.1016/j.biomaterials.2009.01.005
  19. 19. R. Lander, W. Manger, M. Scouloudis, A. Ku, C. Davis and A. Lee, Gaulin homogenization: a mechanistic study, Biotechnol. Prog. 16 (2000) 80-85; DOI: 10.1021/bp990135c.10.1021/bp990135c
  20. 20. R. H. Müller, S. Benita and B. Bohm, Emulsions and nanosuspensions for the formulation of poorly soluble drugs, Int. J. Pharm. 212 (2001) 143-144.10.1016/S0378-5173(00)00604-9
  21. 21. B. Siekmann and K. Westesen, Solid lipid nanoparticles stabilized by tyloxapol, Eur. J. Pharm. Sci. 2 (1994) 117-194; DOI: 10.1016/0928-0987(94)90407-3.10.1016/0928-0987(94)90407-3
  22. 22. H. Bunjes, B. Siekmann and K. Westesen, Emulsions of supercooled melts-a novel drug delivery system, in Submicron Emulsions in Drug Targeting and Delivery, Ed. S. Benita, Hardwood Academic Publishers, Amsterdam 1998, pp. 175-204.10.1201/9780367810528-7
  23. 23. V. Venkateswarlu and K. Manjunath, Preparation, characterization and in-vitro release kinetics of clozapine solid lipid nanoparticles, J. Control. Release 95 (2004) 627-638; DOI: 10.1016/j.jconrel.2004.01.005.10.1016/j.jconrel.2004.01.005
  24. 24. S. Gande, V. Vobalaboina, M. Kopparam, V. Venkateswarlu and S. Vemula, Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles, AAPS PharmSciTech. 8 (2007) E1-E9.10.1208/pt0801024
  25. 25. S. P. Vyas and R. K. Khar, Targeted and Controlled Drug Delivery: A Novel Carrier System, 1st ed., CBS Publishers and Distributors, New Delhi 2002, pp. 346-348.
  26. 26. S. Xie, L. Zhu, Z. Dong, X. Wang, Y. Wang, X. Li and W. Zhou, Preparation, characterization and pharmacokinetics of enrofloxacin loaded solid lipid nanoparticles: Influences of fatty acids, Colloid Surface B 83 (2011) 382-387; DOI: 10.1016/j.colsurfb.2010.12.014; DOI: 10.1016/j.colsurfb.2010.12.014.
  27. 27. A. V. Heydenreich, R. Westmeier, N. Pedersen, H. S. Poulsen and H. G. Kristensen, Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity, Int. J. Pharm. 254 (2003) 83-87; DOI: 10.1016/S0378-5173(02)00688-9.10.1016/S0378-5173(02)00688-9
  28. 28. N. K. Jain, Advances in Controlled and Novel Drug Delivery, 1st ed., CBS Publishers and Distributors, New Delhi 2001, pp. 418-424.
  29. 29. H. Zhou, T. Gu, D. Yang, Z. Jiang and J. Zeng, Griseofulvin solid lipid nanoparticles based on microemulsion technique, Adv. Mater. Res. 197-198 (2011) 47-50; DOI: 10.4028/www.scientific.net/AMR.197-198.47.10.4028/www.scientific.net/AMR.197-198.47
  30. 30. M. R. Gasco and L. P. Antonelli, Method for producing solid lipid nanospheres having a narrow size distribution, US Pat. 5,250,236, 05 Oct. 1993.
  31. 31. S. Morel, M. R. Gasco and R. Cavalli, Incorporation in lipospheres of [D-Trp-6]LHRH, Int. J. Pharm. 105 (1994) RI-R3; DOI: 10.1016/0378-5173(94)90466-9.10.1016/0378-5173(94)90466-9
  32. 32. S. Morel, E. Ugazio, R. Cavalli and M. R. Gasco, Thymopentin in solid lipid nanoparticles, Int. J. Pharm. 132 (1996) 259-261; DOI: 10.1016/0378-5173(95)04388-8.10.1016/0378-5173(95)04388-8
  33. 33. T. Hammady, A. El-Gindy, E. Lejmi, R. S. Dhanikula, P. Moreau and P. Hildgen, Characteristics and properties of nanospheres co-loaded with lipophilic and hydrophilic drug models, Int. J. Pharm. 369 (2009) 185-195; DOI: 10.1016/j.ijpharm.2008.10.034.10.1016/j.ijpharm.2008.10.034
  34. 34. M. Trotta, F. Debernardi and O. Caputo, Preparation of solid lipid nanoparticles by solvent emulsification-diffusion technique, Int. J. Pharm. 257 (2003) 153-160; DOI: 10.1016/S0378-5173(03)00135-2.10.1016/S0378-5173(03)00135-2
  35. 35. L. Battaglia, M. Trotta, M. M. E. G. P. A. Solid lipid nanoparticles formed by solvent-in-eater emulsion-diffusion technique, J. Microencapsul. 5 (2009) 394-402.
  36. 36. H. Yuan, L. F. Huang, Y. Z. Du, X. Y. Ying, J. You, F. Q. Hu and S. Zeng, Solid lipid nanoparticles prepared by solvent diffusion method in nanoreactor system, Colloid Surface B 61 (2008) 132-137; DOI: 10.1016/j.colsurfb.2007.07.015.10.1016/j.colsurfb.2007.07.01517888636
  37. 37. J. Jaiswal, S. K. Gupta and J. Kreuter, Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process, J. Control Release 96 (2004) 169-178; DOI: 10.1016/j.jconrel.2004.01.017.10.1016/j.jconrel.2004.01.017
  38. 38. B. Sjostrom and B. Bergenstahl, Preparation of submicron drug particles in lecithin stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate, Int. J. Pharm. 88 (1992) 53-62; DOI: 10.1016/0378-5173(92)90303-J.10.1016/0378-5173(92)90303-J
  39. 39. K. Okuyama, M. Abdullah, I. W. Lenggoro and F. Iskandar, Preparation of functional nanostructured particles by spray drying, Adv. Powder Technol. 17 (2006) 587-611; DOI: 10.1163/156855206778917733.10.1163/156855206778917733
  40. 40. K. Okuyama and I. W. Lenggoro, Preparation of nanoparticles via spray route, Chem. Eng. Sci. 58 (2003) 537-547; DOI: 10.1016/S0009-2509(02)00578-X.10.1016/S0009-2509(02)00578-X
  41. 41. P. Luo and T. G. Nieh, Synthesis of ultrafine hydroxyapatite particles by spray dry method, Mater. Sci. Eng. C 3 (1995) 75-78; DOI: 10.1016/0928-4931(95)00089-5.10.1016/0928-4931(95)00089-5
  42. 42. C. Freitas and R. H. Müller, Spray-drying of solid lipid nanoparticles (SLNTM), Eur. J. Pharm. Biopharm. 46 (1998) 145-151; DOI: 10.1016/S0939-6411(97)00172-0.10.1016/S0939-6411(97)00172-0
  43. 43. P. Tewa-Tange, S. Briancon and H. Fessi, Preparation of redispersible dry nanocapsules by means of spray-drying: Development and characterisation, Eur. J. Pharm. Sci. 30 (2007) 124-135; DOI: 10.1016/j.ejps.2006.10.006.10.1016/j.ejps.2006.10.006
  44. 44. P. M. Gosselin, R. Thibert, M. Preda and J. N. McMullen, Polymorphic properties of micronized carbamazepine produced by RESS, Int. J. Pharm. 252 (2003) 225-233; DOI: 10.1016/S0378-5173(02)00649-X.10.1016/S0378-5173(02)00649-X
  45. 45. A. J. Thote and R. B. Gupta, Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release, Nanomedicine 1 (2005) 85-90; DOI: 10.1016/j.nano.2004.12.001.10.1016/j.nano.2004.12.001
  46. 46. J. Vandervoort and A. Ludwig, Preparation and evaluation of drug loaded gelatin nanoparticles for topical ophthalmic use, Eur. J. Pharm. Biopharm. 57 (2004) 251-261; DOI: 10.1016/S0939-6411(03)00187-5.10.1016/S0939-6411(03)00187-5
  47. 47. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A. K. Goyal, N. Mishra, A. Mehta and S. P. Vyas, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery, Nanomedicine 5 (2009) 184-191; DOI: 10.1016/j.nano.2008.08.003.10.1016/j.nano.2008.08.003
  48. 48. C. Olbrich and R. H. Müller, Enzymatic degradation of SLN - Effect of surfactant and surfactant mixtures, Int. J. Pharm. 180 (1999) 31-39; DOI: 10.1016/S0378-5173(98)00404-9.10.1016/S0378-5173(98)00404-9
  49. 49. C. C. Chen, T. H. Tsai, Z. R. Huang and J. Y. Fang, Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics, Eur. J. Pharm. Biopharm. 74 (2010) 474-482; DOI: 10.1016/j.ejpb.2009.12.008.10.1016/j.ejpb.2009.12.008
  50. 50. S. Y. Xie, S. L. Wang, B. K. Zhao, C. Han, M. Wang and W. Z. Zhou, Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles, Colloid Surface B 67 (2008) 199-204; DOI: 10.1016/j.colsurfb.2008.08.018.10.1016/j.colsurfb.2008.08.018
  51. 51. R. Cavalli, O. Caputo, M. E. Carlotti, M. Trotta, C. Scarnecchia and M. R. Gasco, Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, Int. J. Pharm. 148 (1997) 47-54; DOI: 10.1016/S0378-5173(96)04822-3.10.1016/S0378-5173(96)04822-3
  52. 52. C. Schwarz, W. Mehnert, J. S. Lucks and R. H. Müller, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterisation and sterilization, J. Control Release 30 (1994) 83-96.10.1016/0168-3659(94)90047-7
  53. 53. W. Abdelwahed, G. Degobert, S. Stainmesse and H. Fessi, Freeze-drying of nanoparticles: Formulation, process and storage considerations, Adv. Drug Del. Rev. 58 (2006) 1688-1713; DOI: 10.1016/j.addr.2006.09.017.10.1016/j.addr.2006.09.017
  54. 54. S. D. Allison, Md. C. Molina and T. J. Anchordoquy, Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis, Biochim. Biophys. Acta. 1468 (2000) 127-138; DOI: 10.1016/S0005-2736(00)00251-0.10.1016/S0005-2736(00)00251-0
  55. 55. J. H. Crowe, J. F. Carpenter and L. M. Crowe, The role of vitrification in anhydrobiosis, Annu. Rev. Physiol. 60 (1998) 73-103; DOI: 10.1146/annurev.physiol.60.1.73.10.1146/annurev.physiol.60.1.73
  56. 56. K. Westesen, B. Siekmann and M. H. J. Koch, Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction, Int. J. Pharm. 93 (1993) 189-199; DOI: 10.1016/0378-5173(93)90177-H.10.1016/0378-5173(93)90177-H
  57. 57. H. Bunjes, K. Westesen and M. H. J. Koch, Crystallization tendencies and polymorphic transitions in triglyceride nanoparticles, Int. J. Pharm. 129 (1996) 159-173; DOI: 10.1016/0378-5173(95)04286-5.10.1016/0378-5173(95)04286-5
  58. 58. A. Z. Muhlen, C. Schwarz and W. Mehnert, Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism, Eur. J. Pharm. Biopharm. 45 (1998) 149-155.10.1016/S0939-6411(97)00150-1
  59. 59. S. Chakraborty, D. Shukla, B. Mishra and S. Singh, Lipid - An emerging platform for oral delivery of drugs with poor bioavailability, Eur. J. Pharm. Biopharm. 73 (2009) 1-15; DOI: 10.1016/j.ejpb.2009.06.001.10.1016/j.ejpb.2009.06.001
  60. 60. A. Radomska-Soukharev, Stability of lipid excipients in solid lipid nanoparticles, Adv. Drug Del. Rev. 59 (2007) 411-418; DOI: 10.1016/j.addr.2007.04.004.10.1016/j.addr.2007.04.004
  61. 61. B. Heurtault, P. Saulnier, B. Pech, J.-E. Proust and J. P. Benoit, Physico-chemical stability of colloidal lipid particles, Biomaterials 24 (2003) 4283-4300; DOI: 10.1016/S0142-9612(03)00331-4.10.1016/S0142-9612(03)00331-4
  62. 62. B. Siekmann and K. Westesen, Thermoanalysis of recrystallization process of melt homogenised glyceride nanoparticles, Colloid Surface B 3 (1994) 159-175.10.1016/0927-7765(94)80063-4
  63. 63. C. Freitas and R. H. Müller, Effect of light and temperature on zeta potential and physical stability of solid lipid nanoparticle (SLNTM) dispersions, Int. J. Pharm. 168 (1998) 221-229.10.1016/S0378-5173(98)00092-1
  64. 64. C. Freitas and R. H. Müller, Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte, J. Microencapsul. 16 (1999) 59-71; DOI: 10.1080/026520499289310.10.1080/026520499289310
  65. 65. C. Freitas and R. H. Müller, Correlation between long term stability of solid lipid nanoparticles (SLNTM) and crystallinity of lipid phase, Eur. J. Pharm. Biopharm. 47 (1999) 125-132.10.1016/S0939-6411(98)00074-5
  66. 66. K. Westesen and B. Siekmann, Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, Int. J. Pharm. 151 (1997) 35-45; DOI: 10.1016/S0378-5173(97)04890-4.10.1016/S0378-5173(97)04890-4
  67. 67. R. H. Müller and S. Heinemann, Fat emulsions for parenteral nutrition. III. Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with low electrolyte load, Int. J. Pharm. 101 (1994) 175-189; DOI: 10.1016/0378-5173(94)90213-5.10.1016/0378-5173(94)90213-5
  68. 68. C. Freitas, J. Lucks and R. H. Müller, Effect of storage conditions on long-term stability of »solid lipid nanoparticles« (SLN) in aqueous dispersion, Eur. J. Pharm. Sci. 2 (1994) 117-194; DOI: 10.1016/0928-0987(94)90411-1.10.1016/0928-0987(94)90411-1
  69. 69. B. Borgstrom, Importance of phospholipids, pancreatic phospholipase A2, and fatty acid for the digestion of dietary fat: in vitro experiments with the porcine enzymes, Gastroenterology 78 (1980) 954-962.
  70. 70. R. O. Scow and T. Olivecrona, Effect of albumin on products formed from chylomicron triacylglycerol by lipoprotein lipase in vitro, Biochim. Biophys. Acta. 487 (1977) 472-486; DOI: 10.1016/0005-2760(77)90217-X.10.1016/0005-2760(77)90217-X
  71. 71. R. Pandey, S. Sharma and G. K. Khuller, Oral solid lipid nanoparticle-based antitubercular chemotherapy, Tuberculosis 85 (2005) 415-420, DOI: 10.1016/j.tube.2005.08.009.10.1016/j.tube.2005.08.009
  72. 72. N. Zhang, Q. Ping, G. Huang, W. Xua, Y. Cheng and X. Han, Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin, Int. J. Pharm. 327 (2006) 153-159; DOI: 10.1016/j.ijpharm.2006.07.026.10.1016/j.ijpharm.2006.07.026
  73. 73. M. D. Joshi and R. H. Müller, Lipid nanoparticles for parenteral delivery of actives, Eur. J. Pharm. Biopharm. 71 (2009) 161-172; DOI: 10.1016/j.ejpb.2008.09.003.10.1016/j.ejpb.2008.09.003
  74. 74. S. A. Wissing, O. Kayser and R. H. Müller, Solid lipid nanoparticles for parenteral drug delivery, Adv. Drug Del. Rev. 56 (2004) 1257-1272; DOI: 10.1016/j.addr.2003.12.002.10.1016/j.addr.2003.12.002
  75. 75. A. Fundarò, O, R. Cavalli, A. Bargoni, D. Vighetto, G. P. Zara and M. R. Gasco, Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue Distribution after i.v. administration to rats, Pharmacol. Res. 42 (2000) 337-343; DOI: 10.1006/phrs.2000.0695.10.1006/phrs.2000.0695
  76. 76. S. C. Yang, L. F. Lu, Y. Cai, J. B. Zhu, B. W. Liang and C. Z. Yanga, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, J. Control. Release 59 (1999) 299-307; DOI: 10.1016/S0168-3659(99)00007-3.10.1016/S0168-3659(99)00007-3
  77. 77. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra and R. S. R. Murthy, Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing mice, J. Control. Release 105 (2005) 185-198; DOI: 10.1016/j.jconrel.2005.02.028.10.1016/j.jconrel.2005.02.02815921775
  78. 78. M. Schafer-Korting, W. Mehnert and H. C. Korting, Lipid nanoparticles for improved topical application of drugs for skin diseases, Adv. Drug Del. Rev. 59 (2007) 427-443; DOI: 10.1016/j.addr.2007.04.006.10.1016/j.addr.2007.04.006
  79. 79. V. Jenning, M. Schafer-Korting and S. Gohla, Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties, J. Control. Release 66 (2000) 115-126; DOI: 10.1016/S0168-3659(99)00007-3.10.1016/S0168-3659(99)00007-3
  80. 80. P. V. Pople and K. K. Singh, Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A, AAPS PharmSciTech. 4 (2006) E1-E7; DOI: 10.1208/pt070491.10.1208/pt070491275032817285742
  81. 81. S. K. Jain, M. K. Chourasia, R. Masuriha, V. Soni, A. Jain, Nitin K. Jain and Y. Gupta, Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery, Drug Del. 12 (2005) 207-215; DOI: 10.1080/10717540590952591.10.1080/1071754059095259116036715
  82. 82. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins, Ad.v Drug Del. Rev. 59 (2007) 478-490; DOI: 10.1016/j.addr.2007.04.007.10.1016/j.addr.2007.04.00717543416
  83. 83. J. Liu, T. Gong, H. Fu, C. Wang, X. Wang, Q. Chena, Q. Zhang, Q. Hea and Z. Zhang, Solid lipid nanoparticles for pulmonary delivery of insulin, Int. J. Pharm. 356 (2008) 333-344; DOI: 10.1016/j.ijpharm.2008.01.008.10.1016/j.ijpharm.2008.01.00818281169
  84. 84. J. Araujo, E. Gonzalez, M. A. Egea, M. L. Garcia and E. B. Souto, Nanomedicines for ocular NSAIDs: safety on drug delivery, Nanomedicine 5 (2009) 394-401; DOI: 10.1016/j.nano.2009.02.003.10.1016/j.nano.2009.02.00319341814
  85. 85. M. I. Alam, S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, A. Ahuja and M. Akbar, Strategy for effective brain drug delivery, Eur. J. Pharm. Sci. 40 (2010) 385-403; DOI: 10.1016/j.ejps.2010.05.003.10.1016/j.ejps.2010.05.00320497904
  86. 86. I. P. Kaur, R. Bhandari, S. Bhandari and V. Kakkar, Potential of solid lipid nanoparticles in brain targeting, J. Control. Release 127 (2008) 97-100; DOI: 10.1016/j.jconrel.2007.12.018.10.1016/j.jconrel.2007.12.01818313785
  87. 87. A. Mistry, S. Stolnik and L. Illum, Nanoparticles for direct nose-to-brain delivery of drugs, Int. J. Pharm. 379 (2009) 146-157; DOI: 10.1016/j.ijpharm.2009.06.019.10.1016/j.ijpharm.2009.06.01919555750
  88. 88. I. Brasnjevic, H. W. M. Steinbusch, C. Schmitz and P. Martinez-Martinez, Delivery of peptide and protein drugs over the blood-brain barrier, Prog. Neurobiol. 87 (2009) 212-251; DOI: 10.1016/j.pneurobio.2008.12.002.10.1016/j.pneurobio.2008.12.002
  89. 89. F. Chellat, Y. Merhi, A. Moreau and L. H. Yahia, Therapeutic potential of nanoparticulate systems for macrophage targeting, Biomaterials 26 (2005) 7260-7275; DOI: 10.1016/j.biomaterials.2005.05.044.10.1016/j.biomaterials.2005.05.044
  90. 90. H. Chen, X. Chang, D. Du, W. Liu, J. Liu, T. Weng, Y. Yang, H. Xu and X. Yang, Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting, J. Control. Release 110 (2006) 296-306; DOI: 10.1016/j.jconrel.2005.09.052.10.1016/j.jconrel.2005.09.052
  91. 91. R. H. Müller, S. Maaben, H. Weyhers, F. Specht and J. S. Lucks, Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles, Int. J. Pharm. 138 (1996) 85-94; DOI: 10.1016/0378-5173(96)04539-5.10.1016/0378-5173(96)04539-5
  92. 92. D. M. Radolfi, P. D. Marcato, R. A. Silva, G. Z. Justo and N. Duran, In vitro cytotoxicity assay of solid lipid nanoparticles in epithelial and dermal cells, J. Phys. Conf. Ser. 304 (2011) 1-4; DOI: 10.1088/1742-6596/304/1/012032.10.1088/1742-6596/304/1/012032
  93. 93. H. Yuan, J. Miao, Y. Z. Du, J. You, F. Q. Hu and S. Zeng, Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells, Int. J. Pharm. 348 (2008) 137-145; DOI: 10.1016/j.ijpharm.2007.07.012.10.1016/j.ijpharm.2007.07.01217714896
  94. 94. J. C. Olivier, Drug transport to brain with targeted nanoparticles, NeuroRx. 1 ( 2005) 108-119; DOI: 10.1602/neurorx.2.1.108.10.1602/neurorx.2.1.10853932915717062
  95. 95. T. R. Pisanic II, J. D. Blackwell, V. I. Shubayev, R. R. Fiñones and S. Jin, Nanotoxicity of iron oxide nanoparticle internalization in growing neurons, Biomaterials 28 (2007) 2572-2581; DOI: 10.1016/j.biomaterials.2007.01.043.10.1016/j.biomaterials.2007.01.04317320946
  96. 96. H. C. Fischer, W. C. Chan, Nanotoxicity: the growing need for in vivo study, Curr. Opin. Biotechnol. 18 (2007) 565-571; DOI: 10.1016/j.copbio.2007.11.008.10.1016/j.copbio.2007.11.00818160274
  97. 97. Y. L. Hu and J. Q. Gao, Potential neurotoxicity of nanoparticles, Int. J. Pharm. 394 (2010) 115-121; DOI: 10.1016/j.ijpharm.2010.04.026.10.1016/j.ijpharm.2010.04.02620433914
  98. 98. K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann and K. Mäder, Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy, J. Control. Release 95 (2004) 217-227; DOI: 10.1016/j.jconrel.2003.11.012.10.1016/j.jconrel.2003.11.012
  99. 99. S. Chakraborty, B. Sahoo, I. Teraoka and R. A. Gross, Solution properties of starch nanoparticles in water and DMSO as studied by dynamic light scattering, Carbohydr Polym. 60 (2005) 475-481; DOI: 10.1016/j.carbpol.2005.03.011.10.1016/j.carbpol.2005.03.011
  100. 100. B. G. Zanetti-Ramos, M. B. Fritzen-Garcia, C. S. de Oliveira, A. A. Pasa, V. Soldi, R. Borsali and T. B. Creczynski-Pasa, Dynamic light scattering and atomic force microscopy techniques for size determination of polyurethane nanoparticles, Mater. Sci. Eng. C. Mater. Biol. App. 29 (2009) 638-640; DOI: 10.1016/j.msec.2008.10.040.10.1016/j.msec.2008.10.040
  101. 101. L. Dulog and T. Schauer, Field flow fractionation for particle size determination, Prog. Org. Coat. 28 (1996) 25-31; DOI: 10.1016/0300-9440(95)00584-6.10.1016/0300-9440(95)00584-6
  102. 102. A. S. Dukhin, P. J. Goetz, X. Fang and P. Somasundaran, Monitoring nanoparticles in the presence of larger particles in liquids using acoustics and electron microscopy, J. Colloid Inter. Sci. 342 (2010) 18-25; DOI: 10.1016/j.jcis.2009.07.001.10.1016/j.jcis.2009.07.001
  103. 103. V. Jenning, K. Mäder and S. H. Gohla, Solid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: 1H-NMR study, Int. J. Pharm. 205 (2000) 15-21; DOI: 10.1016/S0378-5173(00)00462-2.10.1016/S0378-5173(00)00462-2
  104. 104. A. Dubes, H. Parrot-Lopez, W. Abdelwahed, G. Degobert, H. Fessi, P. Shahgaldian and A. W. Coleman, Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins, Eur. J. Pharm. Biopharm. 55 (2003) 279-282; DOI: 10.1016/S0939-6411(03)00020-1.10.1016/S0939-6411(03)00020-1
  105. 105. M. Albrecht, V. Janke, S. Sievers, U. Siegner, D. Schulerb and U. Heyen, Scanning force microscopy study of biogenic nanoparticles for medical applications, J. Magn. Magn. Mater. 290-291 (2005) 269-271; DOI: 10.1016/j.jmmm.2004.11.206.10.1016/j.jmmm.2004.11.206
  106. 106. N. Škalko, J. Bouwstra, F. Spies, M. Stuart, P. M. Frederik and G. Gregoriadis, Morphological observations on liposomes bearing covalently bound protein: Studies with freeze-fracture and cryo electron microscopy and small angle X-ray scattering techniques, Biochim. Biophys. Acta 1370 (1998) 151-160; DOI: 10.1016/S0005-2736(97)00256-3.10.1016/S0005-2736(97)00256-3
  107. 107. K. Fowler, L. A. Bottomley and H. Schreier, Surface topography of phospholipid bilayer and vesicles (liposomes) by scanning tunnelling microscopy (STM), J. Control. Release 22 (1992) 283-292; DOI: 10.1016/0168-3659(92)90103-X.10.1016/0168-3659(92)90103-X
  108. 108. O. Robach, C. Quiros, S. M. Valvidares, C. J. Walker and S. Ferrer, Structure and Pt magnetism of FePt nanoparticles investigated with X-ray diffraction, J. Magn. Magn. Mater. 264 (2003) 202-208; DOI: 10.1016/S0304-8853(03)00205-1.10.1016/S0304-8853(03)00205-1
  109. 109. M. A. Schubert, B. C. Schicke and C. C. Muller-Goymann, Thermal analysis of the crystallization and melting behaviour of lipid matrices and lipid nanoparticles containing high amounts of lecithin, Int. J. Pharm. 298 (2005) 242-254; DOI: 10.1016/j.ijpharm.2005.04.014.10.1016/j.ijpharm.2005.04.014
  110. 110. S. A. Wissing and R. H. Müller, Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration, J. Control. Release 81 (2002) 225-233; DOI: 10.1016/S0168-3659(02)00056-1.10.1016/S0168-3659(02)00056-1
  111. 111. C. Song and S. Liu, A new healthy sunscreen system for human: Solid lipid nannoparticles as carrier for 3,4,5-trimethoxybenzoylchitin and the improvement by adding vitamin E, Int. J. Biol. Macromol. 36 (2005) 116-119; DOI: 10.1016/j.ijbiomac.2005.05.003.10.1016/j.ijbiomac.2005.05.003
  112. 112. J. Pardeike, A. Hommoss and R. H. Müller, Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, Int. J. Pharm. 366 (2009) 170-184; DOI: 10.1016/j.ijpharm.2008.10.003.10.1016/j.ijpharm.2008.10.003
  113. 113. S. A. Wissing and R. H. Müller, Cosmetic applications for solid lipid nanoparticles (SLN), Int. J. Pharm. 254 (2003) 65-68; DOI: 10.1016/S0378-5173(02)00684-1.10.1016/S0378-5173(02)00684-1
  114. 114. K. A. Shah, A. A. Date, M. D. Joshi and V. B. Patravale, Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery, Int. J. Pharm. 345 (2007) 163-171; DOI: 10.1016/j.ijpharm.2007.05.061.10.1016/j.ijpharm.2007.05.06117644288
  115. 115. J. Liu, W. Hu, H. Chen, Q. Ni, H. Xu and X. Yang, Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery, Int. J. Pharm. 328 (2007) 191-195; DOI: 10.1016/j.ijpharm.2006.08.007.10.1016/j.ijpharm.2006.08.00716978810
  116. 116. M. S. Korting, W. Mehnert and H. C. Korting, Lipid nanoparticles for improved topical application of drugs for skin diseases, Adv. Drug Del. Rev. 59 (2007) 427-443; DOI: 10.1016/j.addr.2007.04.006.10.1016/j.addr.2007.04.00617544165
  117. 117. A. del Pozo-Rodrigueza, D. Delgadoa, M. A. Solinis, J. L. Pedraza, E. Echevarria, J. M. Rodriguez and A. R. Gascona, Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration, Int. J. Pharm. 385 (2010) 157-162; DOI: 10.1016/j.ijpharm.2009.10.020.10.1016/j.ijpharm.2009.10.02019835940
  118. 118. S. H. Choi, S. E. Jin, M. K. Lee, S. J. Lim, J. S. Park, B. G. Kim, W. S. Ahn and C. K. Kim, Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells, Eur. J. Pharm. Biopharm. 68 (2008) 545-554; DOI: 10.1016/j.ejpb.2007.07.011.10.1016/j.ejpb.2007.07.011
  119. 119. N. Pedersen, S. Hansen, A. V. Heydenreich, H. G. Kristensen and H. S. Poulsen, Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands, Eur. J. Pharm. Biopharm. 62 (2006) 155-162; DOI: 10.1016/j.ejpb.2005.09.003.10.1016/j.ejpb.2005.09.003
  120. 120. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li and X. Y. Wu, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles, Adv. Drug Del. Rev. 59 (2007) 491-504; DOI: 10.1016/j.addr.2007.04.008.10.1016/j.addr.2007.04.008
  121. 121. H. L. Wong, R. Bendayan, A. M. Rauth and X. Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer, J. Control. Release 116 (2006) 275-284; DOI: 10.1016/j.jconrel.2006.09.007.10.1016/j.jconrel.2006.09.007
  122. 122. R. K. Subedi, K. W. Kang and H. K. Choi, Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin, Eur. J. Pharm. Sci. 37 (2009) 508-513; DOI: 10.1016/j.ejps.2009.04.008.10.1016/j.ejps.2009.04.008
  123. 123. B. Lu, S. B. Xiong, H. Yang, X. D. Yin and R. B. Chao, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases, Eur. J. Pharm. Sci. 28 (2006) 86-95; DOI: 10.1016/j.ejps.2006.01.001.10.1016/j.ejps.2006.01.001
  124. 124. N. Csaba, M. Garcia-Fuentes and M. J. Alonso, Nanoparticles for nasal vaccination, Adv. Drug Del. Rev. 61 (2009) 140-157; DOI: 10.1016/j.addr.2008.09.005.10.1016/j.addr.2008.09.005
  125. 125. S. M. Moghimi and J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463-478; DOI: 10.1016/S0163-7827(03)00033-X.10.1016/S0163-7827(03)00033-X
  126. 126. Y. Wang and W. Wu, In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages, Drug Deliv. 3 (2006) 189-192; DOI: 10.1080/10717540-500-315330.
  127. 127. M. R. Gasco, Lipid nanoparticles: perspectives and challenges, Adv. Drug Del. Rev. 59 (2007) 377-378; DOI: 10.1016/j.addr.2007.05.004.10.1016/j.addr.2007.05.004
  128. 128. A. J. Domb, Long acting injectable oxytetracycline-liposphere formulations, Int. J. Pharm. 124 (1995) 271-278; DOI: 10.1016/0378-5173(95)00098-4.10.1016/0378-5173(95)00098-4
  129. 129. C. Schwarz and W. Mehnert, Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN), Int. J. Pharm. 157 (1997) 171-179; DOI: 10.1016/S0378-5173(97)00222-6.10.1016/S0378-5173(97)00222-6
  130. 130. K. Westesen, H. Bunjes and M. H. J. Koch, Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential, J. Control. Release 48 (1997) 223-236; DOI: 10.1016/S0168-3659(97)00046-1.10.1016/S0168-3659(97)00046-1
  131. 131. K. Westesen, B. Siekmann and M. H. J. Koch, Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction, Int. J. Pharm. 93 (1993) 189-199; DOI: 10.1016/0378-5173(93)90177-H.10.1016/0378-5173(93)90177-H
  132. 132. A. J. Almeida, S. Runge and R. H. Müller, Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters, Int. J. Pharm. 149 (1997) 255-265; DOI: 10.1016/S0378-5173(97)04885-0.10.1016/S0378-5173(97)04885-0
  133. 133. R. Cavalli, E. Peira, O. Caputo and M. R. Gasco, Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with a-cyclodextrins, Int. J. Pharm. 182 (1999) 59-69.10.1016/S0378-5173(99)00066-6
  134. 134. H. Ali, A. B. Shirode, P. W. Sylvester and S. Nazzal, Preparation and in vitro antiproliferative effect of tocotrienol loaded lipid nanoparticles, Colloid Surface A 353 (2010) 43-51; DOI: 10.1016/j.colsurfa.2009.10.020.10.1016/j.colsurfa.2009.10.020
  135. 135. R. Cavalli, S. Morel, M. R. Gasco, P. Chetoni and M. F. Saettone, Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair, Int. J. Pharm. 117 (1995) 243-246; DOI: 10.1016/0378-5173(94)00339-7.10.1016/0378-5173(94)00339-7
  136. 136. S. Morel, E. Terreno, E. Ugazio, S. Aime and M. R. Gasco, NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium(III) complexes, Eur. J. Pharm. Biopharm. 45 (1998) 157-163; DOI: 10.1016/S0939-6411(97)00107-0.10.1016/S0939-6411(97)00107-0
  137. 137. M. R. Gasco, R. Cavalli and M. E. Carlotti, Timolol in lipospheres, Pharmazie 47 (1992) 119-121.
  138. 138. A. A. Attama and C. C. Müller-Goymann, Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity, Colloid Surface A 315 (2008) 189-195; DOI: 10.1016/j.colsurfa.2007.07.035.10.1016/j.colsurfa.2007.07.035
  139. 139. S. Kheradmandia, E. Vasheghani-Farahani, M. Nosrati and F. Atyabi, Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax, Nanomedicine 6 (2010) 753-759; DOI: 10.1016/j.nano.2010.06.003.10.1016/j.nano.2010.06.00320599527
  140. 140. B. D. Kim, K. Na and H. K. Choi, Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan, Eur. J. Pharm. Sci. 24 (2005) 199-205; DOI: 10.1016/j.ejps.2004.10.008.10.1016/j.ejps.2004.10.008
  141. 141. C. Bocca, O. Caputo, R. Cavalli, L. Gabrial, A. Miglietta and M. R. Gasco, Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles, Int. J. Pharm. 175 (1998) 185-193; DOI: 10.1016/S0378-5173(98)00282-8.10.1016/S0378-5173(98)00282-8
  142. 142. T. M. Goppert and R. H. Müller, Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN), Eur. J. Pharm. Biopharm. 60 (2005) 361-372; DOI: 10.1016/j.ejpb.2005.02.006.10.1016/j.ejpb.2005.02.006
  143. 143. H. M. Redhead, S. S. Davis and L. Illum, Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation, J. Control. Release 70 (2001) 353-363.
  144. 144. C. Olbrich, O. Kayser and R. H. Müller, Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) - effect of surfactants, storage time and crystallinity, Int. J. Pharm. 237 (2002) 119-128; DOI: 10.1016/S0378-5173(02)00035-2.10.1016/S0378-5173(02)00035-2
  145. 145. C. C. Shen, W. L. Tseng and M. M. Hsieh, Selective enrichment of aminothiols using polysorbate 20-capped gold nanoparticles followed by capillary electrophoresis with laser-induced fluorescence, J. Chromatogr. A 1216 (2009) 288-293; DOI: 10.1016/j.chroma.2008.11.044.10.1016/j.chroma.2008.11.044
  146. 146. L. D. Marzio, C. Marianecci, M. Petrone, F. Renaldi and M. Carafa, Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20, Colloid Surface B 82 (2011) 18-24; DOI: 10.1016/j.colsurfb.2010.08.004.10.1016/j.colsurfb.2010.08.004
  147. 147. L. H. Reddy, K. Vivek, N. Bakshi and R. S. R. Murthy, Tamoxifen citrate loaded solid lipid nanoparticles (SLN™): Preparation, characterization, in vitro drug release, and pharmacokinetic evaluation, Pharm. Dev. Technol. 11 (2006) 167-177; 2006, DOI: 10.1080/10837450600561265.10.1080/10837450600561265
  148. 148. F. Q. Hu, H. Yuan, H. H. Zhang and M. Fang, Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization, Int. J. Pharm. 239 (2002) 121-128; DOI: 10.1016/S0378-5173(02)00081-9. 10.1016/S0378-5173(02)00081-9
DOI: https://doi.org/10.2478/v10007-012-0040-z | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 433 - 472
Published on: Jan 15, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2013 Chandrakantsing Pardeshi, Pravin Rajput, Veena Belgamwar, Avinash Tekade, Ganesh Patil, Kapil Chaudhary, Abhijeet Sonje, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.